1	Out-of-Pocket Spending for Health Care Within 90 Days of COVID-19 Hospitalization
2	
3 4	Kao-Ping Chua, MD, PhD ^{a,b} , Rena M. Conti, PhD ^c , Nora V. Becker, MD, PhD ^d
5	Affiliations:
6	^a Department of Pediatrics, Susan B. Meister Child Health Evaluation and Research Center,
7	University of Michigan Medical School, Ann Arbor
8	
9 10	Ann Arbor
11	
12	^c Department of Markets, Public Policy, And Law, Institute for Health System Innovation and
13	Policy, Questrom School of Business, Boston University, Boston
14	^d Department of Internal Medicine, Division of Concered Medicine, University of Michigan
15 16	Medical School, Ann Arbor
17	
18	Address correspondence to: Kao-Ping Chua, MD, PhD, 300 North Ingalls St, SPC 5456, Room
19	6E18, Ann Arbor, Michigan 48109-5456. E-mail: chuak@med.umich.edu. Phone: 734-615-
20	8169
21	
22	Conflicts of interest: The authors have no conflicts of interest to disclose.
23	
24	Financial disclosures: none
25	
26	Word count: 1199
27	
28	Date: June 11, 2021
29	

30 ABSTRACT 31 32 **INTRODUCTION:** Millions of U.S. patients have been hospitalized for coronavirus disease 33 2019 (COVID-19). After discharge, these patients often have extensive health care needs, but out-of-pocket burden for this care is poorly described. Using national data, we assessed out-of-34 pocket spending during the 90 days after COVID-19 hospitalization among privately insured and 35 36 Medicare Advantage patients. 37 **METHODS:** In May 2021, we conducted a cross-sectional analysis of the IQVIA PharMetrics[®] 38 39 Plus for Academics Database, a national de-identified claims database. Among privately insured and Medicare Advantage patients hospitalized for COVID-19 between March-June 2020, we 40 calculated mean out-of-pocket spending for care within 90 days of discharge. To contextualize 41 42 results, we repeated analyses for patients hospitalized for bacterial pneumonia. 43 44 **RESULTS:** Among 1,465 COVID-19 patients included, 516 (35.2%) and 949 (64.8%) were covered by private insurance and Medicare Advantage plans. Among these patients, mean (SD) 45 post-discharge out-of-pocket spending was \$534 (1,045) and \$680 (1,360); spending exceeded 46 \$2,000 for 7.0% and 10.3%. Compared with patients with pneumonia, mean post-discharge out-47 of-pocket spending among COVID-19 patients was higher among the privately insured (\$534 vs 48 \$445) and lower among Medicare Advantage patients (\$680 vs \$918). 49 50 51 **CONCLUSIONS:** Out-of-pocket spending for immediate post-discharge care can be substantial for many patients hospitalized for COVID-19. Among Medicare Advantage patients, post-52 discharge out-of-pocket spending was higher after pneumonia hospitalizations, potentially 53 54 because insurer cost-sharing waivers fully covered the costs of COVID-19-related readmissions 55 during the study period. As many insurers allowed such waivers to expire in 2021, it is important 56 to repeat analyses among patients more recently hospitalized for COVID-19. 57

59 INTRODUCTION

60	Millions of U.S. patients have been hospitalized for coronavirus disease 2019 (COVID-
61	19). ¹ After discharge, these patients often have extensive health care needs. ²⁻⁴ However, out-of-
62	pocket burden for this care has been poorly described. Addressing this gap in knowledge is
63	crucial, as substantial out-of-pocket burden for post-discharge care might exacerbate other
64	financial stresses experienced by patients hospitalized for COVID-19, such as loss of savings,
65	income, and employment. ⁴
66	
67	Using national data, we assessed out-of-pocket spending during the 90 days after
68	COVID-19 hospitalization among privately insured and Medicare Advantage patients and
69	determined which services accounted for the most out-of-pocket spending. Analyses can inform
70	policy discussions and public discourse regarding the financial health of COVID-19 survivors.
71	
72	METHODS
73	Study sample. In May 2021, we conducted a cross-sectional analysis of the IQVIA
74	PharMetrics [®] Plus for Academics Database, which contains medical and pharmacy claims from
75	de-identified patients in all U.S. states. Data included 7.7 million patients covered by fully-
76	insured private plans and 1.0 million patients covered by Medicare Advantage plans in 2020.
77	Claims through September 30, 2020 were available at the time of analysis. Because data were
78	de-identified, the Institutional Review Board of the University of Michigan Medical School
79	exempted analyses from human subjects review.
80	

81	We identified hospitalizations for privately insured and Medicare Advantage patients that
82	had a primary diagnosis of COVID-19 (ICD-10-CM diagnosis code U071) and that began and
83	ended between March 1-June 30, 2020. We limited analyses to each patient's first hospitalization
84	during this period. We excluded patients without continuous medical and pharmacy coverage
85	during the 90 days after discharge, patients whose plan was the secondary insurer, and patients
86	with missing out-of-pocket spending data on any claim during the 90 days after discharge.
87	
88	Measures. We calculated mean out-of-pocket spending (sum of deductibles, co-
89	insurance, and co-payments) across all claims during the 90 days after discharge. Additionally,
90	we calculated mean out-of-pocket spending for 14 service categories: additional hospitalizations,
91	nursing facility admissions, outpatient (e.g., office visits), emergency department visits,
92	radiology, laboratory, diagnostic/therapeutic procedures (e.g., colonoscopy, surgery),
93	physical/occupational/speech/respiratory therapy, home health/hospice, transportation, clinician-
94	administered medications (e.g., infusions), durable medical equipment and supplies, pharmacy-
95	dispensed prescriptions, and miscellaneous (see Appendix for details). For context, we repeated
96	analyses among a comparison group of patients hospitalized for bacterial pneumonia. Patients in
97	this group met similar inclusion and exclusion criterion and did not overlap with the main
98	sample.
99	

Statistical analyses. Within payer types, we compared post-discharge out-of-pocket
 spending for COVID-19 and pneumonia patients using a one-part generalized linear model with
 a log link and Poisson variance function, chosen based on the modified Park test.⁵ Models

103	adjusted for age group, sex, Census region of residence, and month of admission. Analyses used
104	SAS 9.4, Stata 15.1 MP, and two-sided hypothesis tests with $\alpha = 0.05$.

105

106 **RESULTS**

107 Of 2,275 COVID-19 patients meeting inclusion criteria, 810 (35.8%) were excluded,

leaving 1,465 patients in the analytic sample. **Table 1** displays sample characteristics. Overall,

109 516 (35.2%) and 949 (64.8%) patients were covered by private insurance and Medicare

110 Advantage plans.

111

Among privately insured patients, mean (SD) post-discharge out-of-pocket spending was 112 \$534 (1,045). For 36 (7.0%) and 15 (2.9%) patients, this spending exceeded \$2,000 and \$4,000. 113 114 Service categories accounting for the most out-of-pocket spending were pharmacy-dispensed 115 prescriptions (\$130; 24.4% of out-of-pocket spending) and hospitalizations (\$111; 20.8%). 116 Among Medicare Advantage patients, mean post-discharge out-of-pocket spending was \$680 117 (1,360). For 98 (10.3%) and 34 (3.6%) patients, this spending exceeded \$2,000 and \$4,000. Service categories accounting for the most out-of-pocket spending were hospitalizations (\$183; 118 27.0%) and nursing facility admissions (\$126; 18.6%) (Table 2). Among privately insured and 119 120 Medicare Advantage patients, 43.5% and 40.3% of out-of-pocket spending for pharmacydispensed prescriptions was for anticoagulants, diabetes drugs (e.g., insulin and sulfonylureas), 121 122 and bronchodilators. In both populations, these medication classes accounted for the 3 highest shares of out-of-pocket spending for pharmacy-dispensed prescriptions. 123 124

125	Table 1 displays characteristics of the 1,374 patients hospitalized for pneumonia included						
126	in analyses. Among the 245 privately insured pneumonia patients, mean (SD) post-discharge out-						
127	of-pocket spending was \$450 (924), compared with \$534 among COVID-19 patients (adjusted						
128	difference: -\$131, 95% CI: -\$135, -\$128). Among the 1,129 Medicare Advantage patients, mean						
129	(SD) post-discharge out-of-pocket spending was \$918 (1,263), compared with \$680 among						
130	COVID-19 patients (adjusted difference: \$291, 95% CI: \$288, \$294). Among 370 Medicare						
131	Advantage patients with additional hospitalizations after a pneumonia hospitalization, 306						
132	(82.7%) had out-of-pocket spending for the additional hospitalizations. Among 206 Medicare						
133	Advantage patients with additional hospitalizations after a COVID-19 hospitalization, 141						
134	(68.1%) had out-of-pocket spending for the additional hospitalizations.						
135							
136	DISCUSSION						
137	During the 90 days after COVID-19 hospitalization, privately insured and Medicare						
138	Advantage patients paid an average of \$534 and \$680 for health care; 7.0% and 10.3% of						
139	patients paid more than \$2,000. For privately insured patients, prescriptions and additional						
140	hospitalizations accounted for the highest shares of out-of-pocket spending. For Medicare						
141	Advantage patients, additional hospitalizations and nursing facility admissions accounted for the						
142	highest shares.						
143							
144	For the privately insured, post-discharge out-of-pocket spending was higher among						
145	patients hospitalized for COVID-19 than among patients hospitalized for pneumonia. Perhaps						
146	surprisingly, the opposite was true for Medicare Advantage patients. A potential explanation is						

147 that some post-discharge care for COVID-19 patients, including readmissions for COVID-19,

were covered by insurer cost-sharing waivers for COVID-19 hospitalizations.⁶ In support of this
possibility, Medicare Advantage patients who were hospitalized for COVID-19 and subsequently
had additional hospitalizations were less likely to have out-of-pocket spending for these
additional hospitalizations compared with pneumonia patients. As many insurers allowed their
cost-sharing waivers to expire in early 2021⁷, post-discharge out-of-pocket spending among
patients hospitalized for COVID-19 could now be higher than among study patients.

154

The pneumonia comparison highlights that out-of-pocket spending after hospitalization 155 156 discharge can be high for many conditions. Even if future studies demonstrate that long-term 157 out-of-pocket spending after COVID-19 hospitalization is not especially great compared with other conditions, this would not detract from the fact that the absolute level of this spending can 158 159 still be substantial for many COVID-19 patients. Moreover, given the high volume of U.S. hospitalizations for COVID-19 to date¹, the number of patients with substantial out-of-pocket 160 spending for post-discharge care may be large. Consequently, monitoring out-of-pocket spending 161 162 and the financial health of these patients is a key clinical and policy priority.

163

This study has limitations. First, analyses only captured the immediate period after COVID-19 hospitalization. Second, the post-discharge period in this study occurred during the early stages of the pandemic, when utilization of health care services decreased sharply owing to social distancing measures and fears of contracting COVID-19.⁸ Post-discharge utilization, and therefore out-of-pocket spending, might be higher now that utilization is approaching prepandemic levels. Third, this study required hospital discharge by June 30, 2020 because a 90-day post-discharge period was needed and claims were complete only through September 30, 2020 at

171	the time of analysis. While necessary, this decision excluded patients with prolonged						
172	hospitalizations who may require intensive post-discharge care. Consequently, analyses likely						
173	underestimate out-of-pocket burden among all COVID-19 survivors. Finally, patients may not be						
174	fully representative of the entire privately insured and Medicare Advantage population.						
175							
176	CONCLUSIONS						
177	In this national cohort of 1,465 patients hospitalized for COVID-19 during March-June						
178	2020, out-of-pocket spending within 90 days of discharge exceeded \$2,000 for approximately 1						
179	in 14 privately insured patients and 1 in 10 Medicare Advantage patients. Future studies should						
180	repeat analyses among patients more recently hospitalized for COVID-19 using longer follow-up						
181	periods.						

182 ACKNOWLEDGEMENTS

- 183 **Author Contributions:** Dr. Chua had full access to all of the data in the study and takes
- responsibility for the integrity of the data and the accuracy of the data analysis.
- 185
- 186 Study concept and design: Chua, Conti, Becker
- 187 *Acquisition of data:* Chua
- 188 Analysis and interpretation of data: Chua, Conti, Becker
- 189 *Drafting of the manuscript:* Chua
- 190 Critical revision of the manuscript: Chua, Conti, Becker
- 191 *Statistical analysis:* Chua
- 192 *Study supervision:* Becker
- 193
- **Funding source:** Funding for purchasing IQVIA data was partially provided by the Susan B.
- 195 Meister Child Health Evaluation and Research Center at the University of Michigan Medical
- 196 School. Dr. Chua's effort is supported by a career development award from the National Institute
- 197 on Drug Abuse (grant number 1K08DA048110-01). The funders played no role in the design and
- 198 conduct of the study; collection, management, analysis, and interpretation of the data;
- 199 preparation, review, or approval of the manuscript; and decision to submit the manuscript for
- 200 publication
- 201
- 202 **Conflicts of interest:** The authors have no conflicts of interest to disclose.
- 203

204 **REFERENCES**

- Centers for Disease Control and Prevention. Covid Data Tracker. [Internet]. 2021;
 <u>https://covid.cdc.gov/covid-data-tracker/#new-hospital-admissions</u>. Accessed June 3, 2021.
- Lavery AM, Preston LE, Ko JY, et al. Characteristics of Hospitalized Covid-19 Patients
 Discharged and Experiencing Same-Hospital Readmission United States, March-August
 2020. MMWR Morb Mortal Wkly Rep. 2020;69(45):1695-1699.
- Weerahandi H, Hochman KA, Simon E, et al. Post-Discharge Health Status and
 Symptoms in Patients with Severe Covid-19. *J Gen Intern Med.* 2021;36(3):738-745.
- 213 4. Chopra V, Flanders SA, O'Malley M, Malani AN, Prescott HC. Sixty-Day Outcomes
 214 among Patients Hospitalized with Covid-19. *Ann Intern Med.* 2021;174(4):576-578.
- 5. Buntin MB, Zaslavsky AM. Too Much Ado About Two-Part Models and Transformation? Comparing Methods of Modeling Medicare Expanditures. *Journ*
- Transformation? Comparing Methods of Modeling Medicare Expenditures. *Journal of Health Economics*. 2004;23:525-542.
- America's Health Insurance Plans. Health Insurance Providers Respond to Coronavirus (Covid-19). [Internet]. 2021; <u>https://www.ahip.org/health-insurance-providers-respond-</u>
 <u>to-coronavirus-covid-19</u>. Accessed May 25, 2021.
- 7. Appleby J. Time to Say Goodbye to Some Insurers' Waivers for Covid Treatment Fees.
 [Internet]. 2021; <u>https://khn.org/news/article/time-to-say-goodbye-to-some-insurers-</u>
 waivers-for-covid-treatment-fees/. Accessed May 25, 2021.
- 8. Cox C, Amin K, Kamal R. How Have Health Spending and Utilization Changed During
 the Coronavirus Pandemic? 2021; <u>https://www.healthsystemtracker.org/chart-</u>
 collection/how have healthcare utilization and spending changed so far during the
- 226 <u>collection/how-have-healthcare-utilization-and-spending-changed-so-far-during-the-</u>
 227 <u>coronavirus-pandemic/#item-start</u>. Accessed June 9, 2021.
- 228

Table 1. Characteristics of patients hospitalized for COVID-19 and pneumonia between March-June 2020, IQVIA PharMetrics[®] Plus for Academics Database

	COVID-19 (n=	1,465) ^a	Pneumonia (n = 1,374) ^b			
	Private insurance	Medicare Advantage	Private insurance	Medicare Advantage		
Number of patients	516	949	245	1,129		
Age in years						
0-17	6 (1.2%)	0 (0.0%)	17 (6.9%)	0 (0.0%)		
18-34	33 (6.4%)	4 (0.4%)	25 (10.2%)	0 (0.0%)		
35-54	226 (43.8%)	44 (4.6%)	86 (35.1%)	67 (5.9%)		
55-64	202 (39.1%)	102 (10.7%)	99 (40.4%)	168 (14.9%)		
65-74	45 (8.7%)	319 (33.6%)	14 (5.7%)	379 (33.6%)		
75-85	3 (0.6%)	319 (33.6%)	4 (1.6%)	350 (31.0%)		
≥ 86	1 (0.2%)	161 (17.0%)	0 (0.0%)	165 (14.6%)		
Sex						
Male	322 (62.4%)	411 (43.3%)	121 (49.4%)	532 (47.1%)		
Female	194 (37.6%)	538 (56.7%)	124 (50.6%)	597 (52.9%)		
Region						
Northeast	150 (29.1%)	467 (49.2%)	25 (10.2%)	146 (12.9%)		
Midwest	122 (23.6%)	308 (32.5%)	56 (22.9%)	617 (54.7%)		
South	165 (32.0%)	110 (11.6%)	113 (46.1%)	275 (24.4%)		
West	76 (14.7%)	62 (6.5%)	51 (20.8%)	90 (8.0%)		
Admission month						
March	85 (48.1%)	143 (54.7%)	117 (24.1%)	447 (23.1%)		
April	248 (18.8%)	519 (20.7%)	59 (16.7%)	261 (21.8%)		
May	97 (16.7%)	196 (9.6%)	41 (11.4%)	246 (15.5%)		
June	86 (16.7%)	91 (9.6%)	28 (11.4%)	175 (15.5%)		
Mean length of stay (SD)	7.9 (8.2)	8.9 (7.9)	4.2 (4.2)	4.6 (3.4)		
Any intensive care unit utilization ^a	239 (46.3%)	339 (35.7%)	86 (35.1%)	437 (38.7%)		

^aAmong 2,275 patients with an initial hospitalization for COVID-19 between March 1-June 30, 2020, 747 were excluded because they lacked continuous enrollment during the 90 days after discharge, 54 because their insurance was not primary, and 8 because of missing data for out-of-pocket spending. We excluded 1 additional patient owing to the occurrence of a hospitalization that had not resulted in discharge by September 30, 2020 (raising the possibility that out-of-pocket spending for this hospitalization was not fully observed). In total, 810 patients were excluded, leaving 1,465 COVID-19 patients.

^bWe identified 1,810 patients who had a hospitalization with a primary diagnosis code for bacterial pneumonia (ICD-10-CM diagnosis code J13-J18) and no secondary diagnosis code for COVID-19 (U017) between March 1-June 30, 2020, and who were not in the sample of 1,465 COVID-19 patients. Of the 1,813 patients, 365 were excluded because they lacked continuous enrollment during the 90 days after discharge, 47 because their insurance was not primary, 22 because of missing data for out-of-pocket spending, and 2 because they had a hospitalization that had not resulted in discharge by September 30, 2020. In total, 436 patients were excluded, leaving 1,374 pneumonia patients.

^cDefined as having at least one claim during the hospitalization with a revenue code for intensive care unit (0200-0209) or coronary care unit (0210-0219).

Table 2. Out-of-pocket spending for health care in the 90 days after COVID-19 hospitalization, IQVIA PharMetrics[®] Plus for Academics Database

	Private insurance (n = 516)					Medicare Advantage (n = 949)				
Service category ^a	No. patients with ≥1 claim (% patients in sample)	Mean (SD) OOP spending per patient in sample	% of all OOP spending	No. patients with OOP spending (% patients in sample)	Mean (SD) OOP spending among patients with OOP spending	No. patients with ≥1 claim (% patients in sample)	Mean (SD) OOP spending per patient in sample	% of all OOP spending	No. patients with OOP spending (% patients in sample)	Mean (SD) OOP spending among patients with OOP spending
Hospitalization	56 (10.9%)	\$111 (638)	20.8%	35 (6.8%)	\$1634 (1896)	206 (21.7%)	\$183 (824)	27.0%	141 (14.9%)	\$1235 (1815)
Nursing facility	2 (0.4%)	\$0(12)	0.1%	1 (0.2%)	\$281 (NA)	221 (23.3%)	\$126 (698)	18.6%	128 (13.5%)	\$936 (1695
Outpatient services	450 (87.2%)	\$44 (100)	8.2%	223 (43.2%)	\$101 (132)	797 (84.0%)	\$36 (57)	5.2%	497 (52.4%)	\$68 (6 <u>4)</u>
ED visits	56 (10.9%)	\$31 (190)	5.9%	25 (4.8%)	\$647 (597)	183 (19.3%)	\$13 (49)	1.9%	103 (10.9%)	\$121 (97)
Radiology tests	223 (43.2%)	\$65 (239)	12.2%	120 (23.3%)	\$280 (431)	404 (42.6%)	\$36 (166)	5.3%	241 (25.4%)	\$142 (30)
Laboratory tests	320 (62.0%)	\$41 (207)	7.8%	139 (26.9%)	\$154 (377)	632 (66.6%)	\$7 (20)	1.0%	282 (29.7%)	\$23 (3) 2
Procedures	188 (36.4%)	\$58 (300)	10.9%	100 (19.4%)	\$301 (628)	485 (51.1%)	\$97 (430)	14.2%	271 (28.6%)	\$338 (75
PT, OT, ST, RT	37 (7.2%)	\$9 (75)	1.7%	16 (3.1%)	\$292 (323)	114 (12.0%)	\$9 (50)	1.3%	58 (6.1%)	\$141 (15) 🛱 🕻 🧧
Home health and hospice	76 (14.7%)	\$6 (72)	1.1%	10 (1.9%)	\$290 (456)	192 (20.2%)	\$3 (14)	0.4%	66 (7.0%)	\$38 (4 j j j
Transportation	11 (2.1%)	\$4 (65)	0.8%	4 (0.8%)	\$526 (595)	162 (17.1%)	\$33 (186)	4.8%	98 (10.3%)	\$319 (4寃夏 💫
Administered medications ^b	98 (19.0%)	\$6 (62)	1.1%	38 (7.4%)	\$78 (216)	214 (22.6%)	\$26 (259)	3.8%	73 (7.7%)	\$332 (884) 5 💦
DME and supplies	476 (92.2%)	\$12 (51)	2.3%	55 (10.7%)	\$114 (115)	906 (95.5%)	\$10 (61)	1.5%	179 (18.9%)	\$56 (13 ² 4) 🛱 🎇
Pharmacy ^c	459 (89.0%)	\$130 (261)	24.4%	420 (81.4%)	\$160 (282)	837 (88.2%)	\$87 (212)	12.9%	649 (68.4%)	\$128 (2 47) § 💆
Miscellaneous	179 (34.7%)	\$15 (131)	2.8%	31 (6.0%)	\$253 (480)	381 (40.1%)	\$14 (118)	2.1%	66 (7.0%)	\$207 (40 <u>4</u>) 5
Any service category	510 (98.8%)	\$534 (1045)	100.0%	453 (87.8%)	\$608 (1095)	939 (98.9%)	\$680 (1360)	100.0%	868 (91.5%)	\$743 (140 <mark>5</mark>) §

OOP – out-of-pocket; ED – emergency department; PT – physical therapy; OT – occupational therapy; ST – speech therapy; RT – respiratory therapy; DME – durable medical equipment; NA: not-applicable

^aThese service categories were based on the Agency for Healthcare Research and Quality Clinical Classification Software algorithm for procedures, v2020-1 (available at https://www.hcup-us.ahrq.gov/toolssoftware/ccs_svcsproc/ccssvcproc.jsp). See Appendix for details.

^bAdministered medications refer to medications administered by clinciains, such as injections and infusions at visits

^cIncludes prescriptions dispensed at pharmacies